Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704288 · ClinicalTrials.gov registry record · Phase 2
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
A Phase 2 study, sponsored by Exelixis.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT00704288 is a Phase 2 study that has completed, run by Exelixis. The registered enrollment target is 222 participants.
The verdict
NCT00704288, a Phase 2 study, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
Interventions
- DRUG XL184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704288
The ClinicalTrials.gov registry entry for NCT00704288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL184 is the first listed.
NCT00704288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704288 about?
NCT00704288 is a clinical study titled "Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme". The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth ...
What is the current status of trial NCT00704288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2008-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00704288?
The interventions under investigation include: XL184 (DRUG).
Who is sponsoring clinical trial NCT00704288?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.